-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since March, a number of pharmaceutical companies have released financing news, such as Xinling Pharmaceutical has completed nearly 100 million yuan of pre-A round of financing, and cell drug CDMO company Spectrum Bio has recently completed nearly 100 million yuan of Pre-A round of financing
.
According to news from the investment community on March 18, Xinling Pharmaceutical recently announced the completion of nearly 100 million yuan of Pre-A round of financing
.
This round of financing will be mainly used to strengthen product research and development, enrich product pipelines and expand professional teams, and further expand Xinling Pharmaceutical's advantages in the core technology of transdermal preparations
.
This round of financing was led by Fuhui Venture Capital, followed by Zhongke Chuangyao Venture Capital, and Qiantuhui Pharmaceutical served as the financial advisor for this round of financing
.
According to the relevant person of Xinling Pharmaceutical, Xinling Pharmaceutical will use the funds obtained from this round of financing to continue to promote the research and development, clinical, NMPA and FDA registration and commercialization of various products of transdermal preparations, laying a solid foundation for the company's future development.
.
The relevant person of Fuhui Ventures said that innovative formulations, especially transdermal patches, are a rapidly developing market in China, and the general trend of domestic substitution is superimposed, and they are firmly optimistic about the future prospects of the industry
.
In addition to the above-mentioned companies, Jiangsu Puxin Biopharmaceutical Co.
, Ltd.
(Pubxin Bio) has also recently completed a Pre-A round of financing of nearly 100 million yuan
.
It is reported that the funds raised by Spectrum Biotech in this round will be used for the operation of the domestic R&D center and the landing of the North Carolina R&D center in the United States, in order to better meet the growing demand for cell drug CDMOs at home and abroad
.
This round of financing was led by Puhua Capital, and the old shareholders Zhengxu Investment and Sun Xingzhe Investment continued to increase their investment
.
According to the relevant person of Spectrum Bio, the immune cell therapy products represented by CAR-T have been successfully industrialized in the world
.
China is very likely to become a large global cell therapy market in the next 10 years
.
With the continuous innovation of cell drug varieties, the number of companies and projects involved in the development continues to increase, and the demand for professional cell drug CDMO services is also increasing
.
A person from PricewaterhouseCoopers said that it is predicted that by 2022, 40 products will be approved for the market in the field of cell and gene therapy.
.
CDMO and related services, as the core value chain of the industry, have high potential for downstream customers and strong R&D scalability; commercialization of end products and policy support are also gradually becoming clear
.
In addition, Shanghai Harvest Medical Technology Co.
, Ltd.
Harvest Integrated Research Organization announced the completion of tens of millions of dollars in Series A financing
.
This round of investment was led by OrbiMed, and the original shareholder Toyokawa Capital continued to raise
.
The financing funds will be mainly used to accelerate the development of HiRO's overseas markets, promote the introduction of talents, promote the improvement of digital clinical management capabilities, and promote multi-center clinical trials in China and around the world
.
Yilian Bio, a new-generation antibody-conjugated drug developer, also recently announced the completion of a US$70 million Series B financing.
This round of financing was jointly led by LYFE Capital (Zhouling Capital) and Qiming Venture Capital.
Legend Capital, Zhengxingu Capital and Honghui Fund (HLC) and others followed suit
.
The funds raised in this round of financing will be mainly used for the clinical trial development of the company's next-generation antibody conjugated drug product pipeline, as well as the early research and development of new conjugated drugs
.
Beijing Baikangxin Biotechnology Co.
, Ltd.
, a domestic microfluidic nucleic acid integrated machine company, also announced the completion of a strategic financing of nearly 100 million yuan.
This round of financing was led by global life science and diagnostic companies, and Haoyue Capital continued to serve as the exclusive finance of this round of financing.
consultant
.
This round of financing will help Baikangxin's large-scale production capacity and the construction of an international marketing system
.
For more information on financing this month, please click [Frequency of Financing in the Pharmaceutical Industry] Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
.
According to news from the investment community on March 18, Xinling Pharmaceutical recently announced the completion of nearly 100 million yuan of Pre-A round of financing
.
This round of financing will be mainly used to strengthen product research and development, enrich product pipelines and expand professional teams, and further expand Xinling Pharmaceutical's advantages in the core technology of transdermal preparations
.
This round of financing was led by Fuhui Venture Capital, followed by Zhongke Chuangyao Venture Capital, and Qiantuhui Pharmaceutical served as the financial advisor for this round of financing
.
According to the relevant person of Xinling Pharmaceutical, Xinling Pharmaceutical will use the funds obtained from this round of financing to continue to promote the research and development, clinical, NMPA and FDA registration and commercialization of various products of transdermal preparations, laying a solid foundation for the company's future development.
.
The relevant person of Fuhui Ventures said that innovative formulations, especially transdermal patches, are a rapidly developing market in China, and the general trend of domestic substitution is superimposed, and they are firmly optimistic about the future prospects of the industry
.
In addition to the above-mentioned companies, Jiangsu Puxin Biopharmaceutical Co.
, Ltd.
(Pubxin Bio) has also recently completed a Pre-A round of financing of nearly 100 million yuan
.
It is reported that the funds raised by Spectrum Biotech in this round will be used for the operation of the domestic R&D center and the landing of the North Carolina R&D center in the United States, in order to better meet the growing demand for cell drug CDMOs at home and abroad
.
This round of financing was led by Puhua Capital, and the old shareholders Zhengxu Investment and Sun Xingzhe Investment continued to increase their investment
.
According to the relevant person of Spectrum Bio, the immune cell therapy products represented by CAR-T have been successfully industrialized in the world
.
China is very likely to become a large global cell therapy market in the next 10 years
.
With the continuous innovation of cell drug varieties, the number of companies and projects involved in the development continues to increase, and the demand for professional cell drug CDMO services is also increasing
.
A person from PricewaterhouseCoopers said that it is predicted that by 2022, 40 products will be approved for the market in the field of cell and gene therapy.
.
CDMO and related services, as the core value chain of the industry, have high potential for downstream customers and strong R&D scalability; commercialization of end products and policy support are also gradually becoming clear
.
In addition, Shanghai Harvest Medical Technology Co.
, Ltd.
Harvest Integrated Research Organization announced the completion of tens of millions of dollars in Series A financing
.
This round of investment was led by OrbiMed, and the original shareholder Toyokawa Capital continued to raise
.
The financing funds will be mainly used to accelerate the development of HiRO's overseas markets, promote the introduction of talents, promote the improvement of digital clinical management capabilities, and promote multi-center clinical trials in China and around the world
.
Yilian Bio, a new-generation antibody-conjugated drug developer, also recently announced the completion of a US$70 million Series B financing.
This round of financing was jointly led by LYFE Capital (Zhouling Capital) and Qiming Venture Capital.
Legend Capital, Zhengxingu Capital and Honghui Fund (HLC) and others followed suit
.
The funds raised in this round of financing will be mainly used for the clinical trial development of the company's next-generation antibody conjugated drug product pipeline, as well as the early research and development of new conjugated drugs
.
Beijing Baikangxin Biotechnology Co.
, Ltd.
, a domestic microfluidic nucleic acid integrated machine company, also announced the completion of a strategic financing of nearly 100 million yuan.
This round of financing was led by global life science and diagnostic companies, and Haoyue Capital continued to serve as the exclusive finance of this round of financing.
consultant
.
This round of financing will help Baikangxin's large-scale production capacity and the construction of an international marketing system
.
For more information on financing this month, please click [Frequency of Financing in the Pharmaceutical Industry] Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
